614 related articles for article (PubMed ID: 18084158)
61. Prevalence of growth and endocrine disorders in Malaysian children with transfusion-dependent thalassaemia.
Tan KA; Lum SH; Yahya A; Krishnan S; Jalaludin MY; Lee WS
Singapore Med J; 2019 Jun; 60(6):303-308. PubMed ID: 30556093
[TBL] [Abstract][Full Text] [Related]
62. New concept in natural history and management of diabetes mellitus in thalassemia major.
Chatterjee R; Bajoria R
Hemoglobin; 2009; 33 Suppl 1():S127-30. PubMed ID: 20001615
[TBL] [Abstract][Full Text] [Related]
63. Iron burden and endocrine complications in transfusion-dependent thalassemia patients In Sarawak, Malaysia: a retrospective study.
Chow LC; Lee BS; Tang SO; Loh EW; Ng SC; Tan XY; Ahmad Noordin MN; Ong GB; Chew LC
Med J Malaysia; 2024 May; 79(3):281-287. PubMed ID: 38817060
[TBL] [Abstract][Full Text] [Related]
64. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
Rodríguez Galindo C; Ortega Aramburu JJ; Alonso JL; Albisu M; Casaldáliga J; Díaz de Heredia C; Olivé T; Bastida P
Med Clin (Barc); 1994 May; 102(19):721-4. PubMed ID: 8041200
[TBL] [Abstract][Full Text] [Related]
65. A cross-sectional study of growth, puberty and endocrine function in patients with thalassaemia major in Hong Kong.
Kwan EY; Lee AC; Li AM; Tam SC; Chan CF; Lau YL; Low LC
J Paediatr Child Health; 1995 Apr; 31(2):83-7. PubMed ID: 7794630
[TBL] [Abstract][Full Text] [Related]
66. The Thalassemia center of Antalya State Hospital: 15 years of experience (1994 to 2008).
Canatan D
J Pediatr Hematol Oncol; 2013 Jan; 35(1):24-7. PubMed ID: 23128337
[TBL] [Abstract][Full Text] [Related]
67. Hypogonadism in male thalassemia major patients: pathophysiology, diagnosis and treatment.
De Sanctis V; Soliman AT; Yassin MA; Di Maio S; Daar S; Elsedfy H; Soliman N; Kattamis C
Acta Biomed; 2018 Feb; 89(2-S):6-15. PubMed ID: 29451224
[TBL] [Abstract][Full Text] [Related]
68. Growth and pubertal development in transfusion-dependent children and adolescents with thalassaemia major and sickle cell disease: a comparative study.
Soliman AT; elZalabany M; Amer M; Ansari BM
J Trop Pediatr; 1999 Feb; 45(1):23-30. PubMed ID: 10191589
[TBL] [Abstract][Full Text] [Related]
69. Short stature and body proportion in thalassaemia.
Caruso-Nicoletti M; De Sanctis V; Capra M; Cardinale G; Cuccia L; Di Gregorio F; Filosa A; Galati MC; Lauriola A; Malizia R; Mangiagli A; Massolo F; Mastrangelo C; Meo A; Messina MF; Ponzi G; Raiola G; Ruggiero L; Tamborino G; Saviano A
J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():811-6. PubMed ID: 10091151
[TBL] [Abstract][Full Text] [Related]
70. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major.
Wonke B; Jensen C; Hanslip JJ; Prescott E; Lalloz M; Layton M; Erten S; Tuck S; Agnew JE; Raja K; Davies K; Hoffbrand AV
J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():795-801. PubMed ID: 10091149
[TBL] [Abstract][Full Text] [Related]
71. Platelet and not erythrocyte microparticles are procoagulant in transfused thalassaemia major patients.
Agouti I; Cointe S; Robert S; Judicone C; Loundou A; Driss F; Brisson A; Steschenko D; Rose C; Pondarré C; Bernit E; Badens C; Dignat-George F; Lacroix R; Thuret I
Br J Haematol; 2015 Nov; 171(4):615-24. PubMed ID: 26205481
[TBL] [Abstract][Full Text] [Related]
72. [Endocrine syndromes in hemochromatosis].
Bricaire H; Luton JP; Modigliani E; Valcke JC
Ann Med Interne (Paris); 1971 Dec; 122(12):1225-34. PubMed ID: 4339575
[No Abstract] [Full Text] [Related]
73. Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination.
Kattamis CA; Kattamis AC
Semin Hematol; 1995 Oct; 32(4):269-79. PubMed ID: 8560284
[No Abstract] [Full Text] [Related]
74. Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment.
Dahlui M; Hishamshah MI; Rahman AJ; Aljunid SM
Singapore Med J; 2009 Aug; 50(8):794-9. PubMed ID: 19710979
[TBL] [Abstract][Full Text] [Related]
75. A cross-sectional study of metabolic and endocrine complications in beta-thalassemia major.
Najafipour F; Aliasgarzadeh A; Aghamohamadzadeh N; Bahrami A; Mobasri M; Niafar M; Khoshbaten M
Ann Saudi Med; 2008; 28(5):361-6. PubMed ID: 18779644
[TBL] [Abstract][Full Text] [Related]
76. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major.
Telfer PT; Prestcott E; Holden S; Walker M; Hoffbrand AV; Wonke B
Br J Haematol; 2000 Sep; 110(4):971-7. PubMed ID: 11054091
[TBL] [Abstract][Full Text] [Related]
77. Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients.
Gamberini MR; Fortini M; Gilli G; Testa MR; De Sanctis V
J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():867-9. PubMed ID: 10091159
[TBL] [Abstract][Full Text] [Related]
78. History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with β thalassemia major.
Ang AL; Tzoulis P; Prescott E; Davis BA; Barnard M; Shah FT
Eur J Haematol; 2014 Mar; 92(3):229-36. PubMed ID: 24164584
[TBL] [Abstract][Full Text] [Related]
79. Morbidities and mortality in transfusion-dependent Beta-thalassemia patients (single-center experience).
Mokhtar GM; Gadallah M; El Sherif NH; Ali HT
Pediatr Hematol Oncol; 2013 Mar; 30(2):93-103. PubMed ID: 23301991
[TBL] [Abstract][Full Text] [Related]
80. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia.
Flanagan JM; Steward S; Hankins JS; Howard TM; Neale G; Ware RE
Am J Hematol; 2009 Jun; 84(6):328-34. PubMed ID: 19384939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
